Story highlights The Pfizer teen nasal vaccine is still a work in progress, but it saw a huge response from its first trial
The ongoing Phase 2 trial will analyze the vaccine’s ability to prevent adverse events
The company recently released some followup results from its adolescent COVID trial.
The Phase 2 trial yielded positive results for the drug COVID, and those results spurred shares of Pfizer Inc. to jump 7% last week.
The recent data, which was published in the New England Journal of Medicine, revealed that the teens with asthma who received the COVID vaccine had slightly lower blood pressure than those who did not receive the vaccine.
The group also performed better on standard lung function tests than those who did not receive the COVID vaccine. It seems that COVID is working.
The Associated Press reports that the adolescent COVID vaccine is still a work in progress — its duration of action has yet to be determined. However, it may be available to children as young as 5 years old at some point.
Pfizer has previously developed this vaccine for adults in order to prevent infections and premature deaths in pregnant women. (It is also currently in the middle of a Phase 3 trial for adults in the US.)
For its COVID vaccine, it has partnered with MedImmune, a subsidiary of AstraZeneca PLC.
While the COVID vaccine is still in the early stages of development, should its future be successful, it could greatly affect those at risk for the disease. Last year, it was estimated that there are 130 million Americans currently living with asthma.
If the COVID vaccine pans out, it would be a boon for both adults and children with asthma.
Editor’s Note: The content of this article is excerpted from a post on Stockpickr.
The post Pfizer’s COVID vaccine helps moderate asthma returns to investors appeared first on Smarter Investing